Actively Recruiting
Safety and Kidney Protection Study of ALE.F02 Infusions in Patients with ANCA-Associated Vasculitis and Rapidly Progressive Glomerulonephritis
Led by Alentis Therapeutics AG · Updated on 2026-08-14
80
Participants Needed
53
Research Sites
34 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying a new drug called ALE.F02 to see if it can protect and preserve kidney function in people with antineutrophil cytoplasmic antibody ANCA associated vasculitis AAV. AAV is an autoimmune disease where the bodys immune system attacks small blood vessels, often affecting the kidneys. This Phase 2 trial aims to evaluate the safety, tolerability, and kidney-protective effects of ALE.F02 when added to standard therapy for rapidly progressive glomerulonephritis RPGN caused by AAV. Participants will be randomly assigned to one of four groups standard treatment plus low, high, or maximum dose ALE.F02 infusions, or standard treatment plus placebo infusions. The treatment period lasts 24 weeks, during which participants receive 13 intravenous infusions alongside standard therapies like Rituximab, glucocorticoids, or cyclophosphamide. The study includes detailed monitoring such as blood and urine tests, pharmacokinetics, antidrug antibody testing, biomarker measurements, pregnancy tests for women, and lung CT scans at baseline and Week 24 if lung involvement is detected. During the study, participants will undergo physical exams and provide samples to assess kidney function and safety. Researchers will measure the primary outcome of safety and tolerability of ALE.F02 up to one year. Secondary outcomes include changes in kidney function markers like estimated glomerular filtration rate eGFR and urine protein levels up to 52 weeks. Participants exposure to glucocorticoids and immunosuppressants will also be tracked. The total study duration extends through treatment and follow-up, with ongoing assessments to understand the drugs effects and safety profile.
CONDITIONS
Brief Title
Rescue of Nephrons With ALE.F02 (RENAL-F02)
Research Team
M
Mohamed Benabed
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here